Biotech Startups

48Hour Discovery is a drug discovery company using chemically modified phage display technology to identify peptide leads with high affinity and specificity. It serves pharmaceutical companies and startups, taking peptide discovery projects from inception through synthesis, validation, and optimization for a range of protein and cell-based targets.

1 investor

4bases develops clinically-validated diagnostic genetic tests, including companion diagnostics and tests for inherited gene mutations, used by healthcare professionals to support therapeutic decisions in precision and preventive medicine. The company operates as an ISO13485-certified, CE-IVD compliant in vitro diagnostics provider.

1 investor

4BIO Capital is an investment firm focused on early-stage advanced therapies targeting chronic disease. The team combines academic researchers, physician-scientists, and investment professionals with direct experience in gene therapy and clinical research.

1 investor

4B Tech develops therapeutics for central nervous system and neurodegenerative diseases, focusing on neuroprotection, synaptic repair, and suppression of neuroinflammation to slow disease progression. Its approach targets the underlying pathophysiology of neural degeneration rather than specific disease causes.

1 investor

4C Biomed develops an immunological screening platform to identify drug targets for cancer immunotherapy development. The company serves pharmaceutical and biotech organizations working on novel cancer treatments.

1 investor

4DMedical develops analytical software that extracts detailed lung function data from standard X-ray and CT scans, enabling non-invasive diagnosis and tailored treatment of respiratory conditions. Its technology serves clinicians and healthcare providers, including VA hospitals treating veterans exposed to toxic substances and airborne hazards.

1 investor

4G Clinical builds randomization and trial supply management (RTSM) technology for complex clinical trials, serving biotech, biopharma, and CRO sponsors. Its software handles randomization, drug supply forecasting, scenario modeling, and system integrations across the study lifecycle.

1 investor

64x provides a platform and product suite for manufacturing advanced therapeutics, including gene therapies, cell therapies, and biologics. The company uses massively parallelized screening and computational insights to engineer high-yield cell lines and production technologies that accelerate the manufacturing of next-generation medicines.

1 investor

65LAB accelerates drug discovery and therapeutic company formation by connecting academic research institutions, life science investors, and Evotec to develop novel medicines into commercial entities. The organization identifies promising therapeutic projects, provides funding up to USD 1.5 million, and mentoring to achieve preclinical proof-of-concept before potential spinout.

1 investor

83 Sciences converts unpublished experimental research data into academic papers, patents, and commercialization opportunities for research organizations. The platform captures laboratory data and uses AI to identify valuable findings within discarded experimental datasets.

1 investor

858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors. Its lead program, ETX-19477, is an oral, selective PARG inhibitor being tested in a Phase 1/2 clinical study.

1 investor

9Bio develops cancer therapies by combining structural biology, artificial intelligence, and protein engineering to create novel oncology treatments. The company focuses on conditionally active therapeutics for cancer patients.

1 investor

A2 Biotherapeutics develops cell therapy technology using the Tmod platform, which applies quantitative drug discovery methods to treat cancer patients.

1 investor

Aakha Bio develops multi-specific antibodies for solid tumors that block disease pathways and activate immune cells. The company targets cancer patients with limited treatment options using a platform approach that integrates multiple therapeutic mechanisms into single molecules.

1 investor

Abalos Therapeutics develops immunotherapy treatments using arenavirus-based approaches for cancer. The company serves cancer patients and is located in Germany, operating in the biotech sector.

1 investor

Abarceo Pharma is a pre-clinical stage biotech developing a small molecule platform targeting mitochondrial dysfunction via the VDAC1 protein, with an initial focus on treatments for Type 2 Diabetes. A spin-out of Lund University Diabetes Center, it also aims at related mitochondrial conditions such as cardiovascular disease and Alzheimer's disease.

1 investor

AbbraTech develops a platform technology for the discovery, engineering, and validation of antibodies, targeting disease-relevant proteins that are difficult to address with conventional approaches. It works with industry and academic partners to develop antibody therapies for conditions such as cancer, immune disorders, and viral infections.

1 investor

AbelZeta develops T cell immunotherapies, advancing pipeline drug candidates through early-stage and investigator-initiated clinical trials to treat cancer and immune and inflammatory (I&I) diseases. The company runs an in-house platform for cell therapy development and partners with global pharmaceutical firms for clinical development and commercialization.

1 investor

Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.

1 investor

Abilita Therapeutics is a drug discovery company focused on membrane protein targets, using its EMP (Enabled Membrane Proteins) technology based on directed evolution to create stability- and expression-enhanced protein variants for discovering and optimizing drug candidates.

1 investor

Ability is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer. Its AbiLeap discovery engine uses AI and a database of antibody sequences to generate fully-human monospecific and bispecific antibodies, with a lead program targeting inflammatory skin diseases and other candidates for solid tumors.

1 investor

Abingworth is a venture capital and private equity firm specializing in life sciences and healthcare investments across seed, development, and clinical co-development stages. The firm manages 15 dedicated funds and has invested in over 200 companies across the United States and Europe.

1 investor

AbInitio uses AI models to predict molecular properties, optimize bioprocess conditions, and recommend cell line and media selections for biopharmaceutical development. The company serves pharma and biotech teams to accelerate the path from drug candidate to commercial manufacturing scale.

1 investor

1 investor